Jacobio-B (JACOBIO PHARMACEUTICALS GROUP CO., LTD.) reported a share repurchase of 36,000 ordinary shares on 31 March 2026, according to its latest Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The on-market transaction was executed at prices between HK$6.92 and HK$6.95 per share, delivering a volume-weighted average price of HK$6.94 and an aggregate consideration of HK$0.25 million. All repurchased shares are being held in treasury.

Following the buyback, the company’s outstanding share count (excluding treasury shares) fell by 36,000 to 786.00 million, a marginal 0.0046% reduction. Treasury shares increased to 5.75 million, while total issued shares remained unchanged at 791.76 million.

The repurchase forms part of the mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulative repurchases under this mandate have reached 2.73 million shares, representing 0.35% of the issued share capital on the mandate approval date.

In line with Main Board Rule 10.06, Jacobio-B is subject to a moratorium on new share issues or disposals of treasury shares until 30 April 2026.